This is a preview of subscription content, access via your institution
Access options
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.

References
Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 2008; 14: 859–866.
Schriber J, Agovi M, Ho V, Ballen KK, Bacigalupo A, Lazarus HM et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 2005; 16: 1099–1106.
Platzbecker U, Binder M, Schmid C, Rutt C, Ehninger G, Bornhäuser M . Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation. Haematologica 2008; 93: 1276–1278.
Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011; 96: 1838–1845.
Larocca A, Piaggio G, Podestà M, Pitto A, Bruno B, Di Grazia C et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006; 91: 935–940.
Remberger M, Ringdén O, Ljungman P, Hägglund H, Winiarski J, Lönnqvist B et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 22: 73–78.
Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W . Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404–1407.
Milone G, Tornello A, Leotta S, Poidomani M, Mercurio S, Farsaci B et al. CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. Bone Marrow Transplant 2005; 35: 521–522.
Mohty M, Faucher C, Chabannon C, Vey N, Stoppa AM, Ladaique P et al. CD34(+) immunoselected cells for poor graft function following allogeneic BMT. Cytotherapy 2000; 2: 367–370.
Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay J-O et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152: 331–339.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Askaa, B., Fischer-Nielsen, A., Vindeløv, L. et al. Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant 49, 720–721 (2014). https://doi.org/10.1038/bmt.2014.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.5
This article is cited by
-
Improving allogeneic stem cell transplantation in myelofibrosis
International Journal of Hematology (2022)
-
Outcomes of allogeneic haematopoietic stem cell transplantation for patients with severe aplastic anaemia using the porcine antilymphocyte globulin-containing conditioning regimen
Annals of Hematology (2020)
-
The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function
Bone Marrow Transplantation (2016)
-
The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation
Annals of Hematology (2015)
-
Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation
Journal of Cancer Research and Clinical Oncology (2015)